Agoracom: Small Cap Investment - Critical Outcome Technologies Inc

Welcome To The Critical Outcome Technologies Inc HUB On AGORACOM

Our disease Targets > Small cell lung cancer, Multiple sclerosis, HIV Integrase, Colorectal cancer & Adult acute leukemia

Reply New Message

Back To Forum List View

Clavis

Rank: President [?]

Points: 26378 [?]

Votes: 242 Score: 3.6 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

To Present at BioFinance 2009

posted on Apr 27, 2009 12:22PM

April 27, 2009

Critical Outcome Technologies Inc. to Present at BioFinance 2009

LONDON, ONTARIO--(Marketwire - April 27, 2009) - Critical Outcome Technologies Inc. (TSX VENTURE:COT), announced today that Dr. Wayne Danter, President and Chief Scientific Officer, will present a corporate update at BioFinance on Wednesday, April 29, 2009 at 9:00 a.m. EDT in the Trinity II room of the Toronto Marriott Eaton Centre. A copy of the corporate update will be available on COTI's website following Dr. Danter's presentation.

COTI will also be represented at BioFinance by Mr. Michael Barr, Director of Business Development and Marketing and Mr. Bruno Maruzzo, a member of COTI's Board of Directors.

About BioFinance 2009

BioFinance 2009 is the leading investor conference in Canada for the life sciences and cleantech industries. This three-day event brings together key industry players interested in investment opportunities and issues affecting companies in the life sciences and cleantech sectors. Participants include senior life science executives, institutional and private equity investors, industry analysts, corporate finance executives and experts from the scientific and medical communities in Canada, the US and Europe.

About Critical Outcome Technologies Inc. (COTI)

COTI is formed around a unique computational platform technology called CHEMSAS(R), which allows for the accelerated identification, profiling and optimization of targeted small molecules potentially effective in the treatment of human diseases for which current therapy is either lacking or ineffective. COTI's business is focused on the discovery and preclinical development of libraries of novel, optimized lead molecules for the treatment of specific cancers, HIV and multiple sclerosis. Currently, five targeted libraries of lead compounds are under active development: small cell lung cancer, HIV integrase inhibitors, acute adult leukemia, multiple sclerosis and colorectal cancer.

For further information, please visit the website at www.criticaloutcome.com.

1 Recommendations

Reply New Message

Back To Forum List View

Please to post a reply